Novartis AG ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
6.4%projected annual EPS growth
Analyst Coverage
11analysts covering
FY EPS (est.)
$8.80next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results | 27 Oct 2026 |
| Meet Novartis Management 2026 (London) | 19 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Strategic Innovative Therapies Patient Reach AnnuallyTarget: 1.6 million patients by 2025 (200% increase)
Flagship Programs Patient Reach AnnuallyTarget: 22.6 million patients by 2025 (50% increase)
Watch Items
- Entresto Generic Erosion and Sales DeclineTrigger: Sales drop exceeding 50% in key quarters following US patent lossAction: Monitor scaling of replacement growth brands (Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix) to offset the margin impact.
- Late-Stage Pipeline Trial Readouts (Pelacarsen, Remibrutinib, Del-desiran)Trigger: Phase III data releases expected in late 2026 / early 2027Action: Evaluate clinical efficacy and regulatory submission timelines to secure the next $10 billion peak sales opportunity.
Research as of 2 Sep 2026